US pharma major GSK yesterday announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant ...
GSK (GSK) announced new preliminary data for AREXVY in adults aged 18-49 at increased risk for lower respiratory tract disease, LRTD, caused by ...
“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...
A new vaccines drug substance facility and R&D pilot plant, completed by the end of 2028, will create over 200 new jobs.
GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...
GSK (GSK) reported its RSV vaccine Arexvy elicited a robust immune response in people aged 18 to 49 years who were at ...
New data for Arexvy, GSK’s RSV vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease: London, UK Friday, October 25, 2024, 13:00 Hr ...
While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...
Hosted on MSN1d
GSK’s Arexvy Vaccine Shows Promise for Broader UseGlaxoSmithKline (GB:GSK) has released an update. GSK has announced promising new data for its RSV vaccine, Arexvy, which ...
The CDC’s vaccine advisors on Thursday maintained that respiratory syncytial virus immunization is only recommended for ...
Earlier this year, GSK said it would invest £200 million (around $260 million) in upgrades to its manufacturing network in ...
Undervalued by 30%, the shares of this wide-moat company look appealing today.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback